276 related articles for article (PubMed ID: 26175180)
1. Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity.
Wheatley AK; Kent SJ
Expert Rev Vaccines; 2015; 14(9):1227-39. PubMed ID: 26175180
[TBL] [Abstract][Full Text] [Related]
2. Strategies towards universal pandemic influenza vaccines.
He F; Leyrer S; Kwang J
Expert Rev Vaccines; 2016; 15(2):215-25. PubMed ID: 26641724
[TBL] [Abstract][Full Text] [Related]
3. Universal influenza vaccines, science fiction or soon reality?
de Vries RD; Altenburg AF; Rimmelzwaan GF
Expert Rev Vaccines; 2015; 14(10):1299-301. PubMed ID: 26104835
[TBL] [Abstract][Full Text] [Related]
4. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
5. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
[TBL] [Abstract][Full Text] [Related]
6. The Quest for a Universal Flu Vaccine: Headless HA 2.0.
Krammer F
Cell Host Microbe; 2015 Oct; 18(4):395-7. PubMed ID: 26468743
[TBL] [Abstract][Full Text] [Related]
7. Vaccine approaches conferring cross-protection against influenza viruses.
Vemula SV; Sayedahmed EE; Sambhara S; Mittal SK
Expert Rev Vaccines; 2017 Nov; 16(11):1141-1154. PubMed ID: 28925296
[TBL] [Abstract][Full Text] [Related]
8. Novel universal influenza virus vaccine approaches.
Krammer F
Curr Opin Virol; 2016 Apr; 17():95-103. PubMed ID: 26927813
[TBL] [Abstract][Full Text] [Related]
9. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.
Cho A; Wrammert J
Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684
[TBL] [Abstract][Full Text] [Related]
10. Towards a universal influenza vaccine: different approaches for one goal.
Sautto GA; Kirchenbaum GA; Ross TM
Virol J; 2018 Jan; 15(1):17. PubMed ID: 29370862
[TBL] [Abstract][Full Text] [Related]
11. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
[TBL] [Abstract][Full Text] [Related]
12. Options and obstacles for designing a universal influenza vaccine.
Jang YH; Seong BL
Viruses; 2014 Aug; 6(8):3159-80. PubMed ID: 25196381
[TBL] [Abstract][Full Text] [Related]
13. Progress in the Development of Universal Influenza Vaccines.
Sun W; Luo T; Liu W; Li J
Viruses; 2020 Sep; 12(9):. PubMed ID: 32957468
[TBL] [Abstract][Full Text] [Related]
14. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
[TBL] [Abstract][Full Text] [Related]
15. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
[TBL] [Abstract][Full Text] [Related]
16. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
Settembre EC; Dormitzer PR; Rappuoli R
J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
[TBL] [Abstract][Full Text] [Related]
17. Emerging influenza viruses and the prospect of a universal influenza virus vaccine.
Krammer F
Biotechnol J; 2015 May; 10(5):690-701. PubMed ID: 25728134
[TBL] [Abstract][Full Text] [Related]
18. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice.
Inn KS; Lee GJ; Quan FS
Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853
[TBL] [Abstract][Full Text] [Related]
19. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice.
Liu Q; Xue C; Zheng J; Liu K; Wang Y; Wei Y; Liu GD; Cao Y
Vaccine; 2015 Jul; 33(32):4035-40. PubMed ID: 26100927
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
